Double Helix Biotechnology Dev. has been acquired by Interpublic Group of Companies
June 2012 — Double Helix Bio-Technology Development Ltd. (Double Helix), a leading, global provider of market research and market access services to the pharmaceutical and medical device industries, has been sold to McCann Health, owned by The Interpublic Group of Companies Inc. Financial details of this transaction have not been disclosed.
Founded by Dr Wayne Phillips and based in London, Double Helix not only specializes in the established markets of the US and Europe, but also focuses on emerging markets, providing clients with a truly global perspective. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients. Dr Phillips will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.
McCann Health is a part of McCann Worldgroup, the largest marketing communications agency network in the world, and is a leading healthcare agency network owned by The Interpublic Group of Companies Inc.
Our role in the transaction
Oaklins Cavendish, based in the UK, acted as financial advisor to the seller.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value
OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.
Learn more360 Experience Group has merged with GoodFellows
360 Experience Group, a European end-to-end service provider of live experiences, and GoodFellows have merged to create one of the largest live experiences players in Europe. By pooling their strengths under the 360 Experience Group banner, the merged group will span the full breadth of the live industry and bring together 16 specialized companies, including Live Legends, Unlimited Productions, Unbranded, TIG Sports and Events and Kumpany. The group will provide end-to-end solutions for the realization of large-scale live entertainment, international sports and public events and impactful brand activations. The combined business will generate over US$90 million in revenue and employ more than 230 people.
Learn moreUKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn more